Japan’s Takeda Plans Friendly Takeover Of Millennium Of U.S.
This article was originally published in PharmAsia News
Takeda Pharmaceutical, Japan's largest drug maker, plans to acquire Millennium Pharmaceuticals of the United States for $8.8 billion. The friendly merger is expected to give Takeda access to Millennium's oncology drugs such as its Velcade (bortezomib) to treat blood-cancer. Takeda and Millennium said in a joint statement the buy was subject to approval of the U.S. firm's shareholders. (Click here for more
You may also be interested in...
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.